Articles From: Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings to Actions Semiconductor Reports Third Quarter 2014 Results


Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Actavis’ pending acquisition of Allergan.
Sign-up for Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings investment picks
DUBLIN and CHICAGO , Oct.
Sign-up for Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata investment picks
- Potential Treatment of Both Schizophrenia and Manic or Mixed Episodes Associated with Bipolar I Disorder - DUBLIN and BUDAPEST, Hungary , Jan.
Sign-up for Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine investment picks
- Earnings and Business Update Scheduled for February 18th - DUBLIN , Jan.
Sign-up for Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance investment picks
DUBLIN , Nov.
Sign-up for Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 investment picks
- Brent Saunders to Lead as CEO and President - - Leadership Reflects Exceptional Combined Expertise of Actavis and Allergan - - Commercial Leadership Operating Model to Optimize Allergan Expertise and Capitalize on Expanded Global Footprint - - Brand Research & Development to Report Directly to CEO - - Enhanced Linkage between Global Operations, Generic R&D and Generic Commercial Markets - DUBLIN , Dec.
Sign-up for Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition investment picks
DUBLIN , Oct.
Sign-up for Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent investment picks
2015/1/12
By Michael Calia Actavis PLC, which is in the process of acquiring of Botox maker Allergan Inc., said it expects its fourth-quarter results to top analysts' expectations, capping what Chief Executive Brent Saunders called an "exceptional year" for the company.
Sign-up for Actavis Expects Profit to Beat Expectations investment picks
By Michael Calia Pharmaceutical company's deal to buy Allergan clears U.S. antitrust wait Actavis PLC, which is in the process of acquiring of Botox maker Allergan Inc., said it expects its fourth-quarter results to top analysts' expectations, capping what Chief Executive Brent Saunders called an "exceptional year" for the company.
Sign-up for Actavis expects profit to beat expectations investment picks
DUBLIN , Dec.
Sign-up for Actavis Launches Generic Version of Celebrex® investment picks
DUBLIN , Dec.
Sign-up for Actavis Launches Generic Version of Intuniv® investment picks
- Products to be Marketed to Clinics and Hospitals across the United States - - Industry-Leading Pipeline in Development - DUBLIN , Jan.
Sign-up for Actavis Launches U.S. Generic Specialty Injectable Portfolio investment picks
- Expertise in global finance, M&A, business development - - Will join Actavis effective December 8, 2014 - DUBLIN , Nov.
Sign-up for Actavis Names Maria Teresa Hilado Chief Financial Officer investment picks
- Increases Second Half Non-GAAP EPS Forecast to $6.60-$6.70 - - 158% Increase in Third Quarter 2014 Adjusted EBITDA to $1.3 billion - - North American Brands Revenues of $1.6 billion; North American Generics and International Revenues of $1.6 billion - - Debt Repayment of ~$750 million During Quarter - - Business Development Initiatives Expand Portfolios; Significant Progress in Integration/Synergy Capture - - GAAP Loss Per Diluted Share in Third Quarter of $3.95 - DUBLIN , Nov.
Sign-up for Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 investment picks
By Russ Britt, MarketWatch Actavis shares jump 5.5% while Allergan rises 1.4% LOS ANGELES (MarketWatch) -- This has got to be a new one in the merger game: the buyer's shares have gone up more than the company it's buying.
Sign-up for Actavis shares outpace buyout target's gains investment picks
- Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares - - Fastest Growing, Most Dynamic Pharmaceutical Company in Global Healthcare - - Leading Blockbuster Franchises in Ophthalmology, Neurosciences/CNS, Medical Aesthetics/Dermatology/Plastic Surgery, Women's Health, Gastroenterology and Urology - - Positioned for Long-Term Double-Digit Organic Revenue and Earnings Growth - - Double-Digit Accretion to Non-GAAP EPS within First 12 Months - - Expands International Presence with Greater Market and Product Reach - - Projected Synergies of at Least $1.8 Billion while Maintaining R&D Commitment of Approximately $1.7 Billion - - Free Cash Flow Generation of more than $8 Billion expected in 2016 - - Investment Grade Rating Expected to be Maintained; Rapid Deleveraging to Below 3.5x Debt to Adjusted EBITDA within 12 Months - - Closing Anticipated in Q2 2015 - DUBLIN and IRVINE, Calif.
Sign-up for Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue investment picks
By Jonathan D.
Sign-up for Actavis to buy Allergan in $66 billion deal investment picks
DUBLIN , Dec.
Sign-up for Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference investment picks
By Jonathan D.
Sign-up for Actavis, Allergan close to a deal investment picks
ZHUHAI, China , Jan.
Sign-up for Actions Launches Single-Chip Bluetooth 4.0 Multimedia Solution investment picks
ZHUHAI, China , Nov.
Sign-up for Actions Semiconductor Reports Third Quarter 2014 Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings to Actions Semiconductor Reports Third Quarter 2014 Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent